PL419327A1 - Peptydy immunosupresyjne i ich zastosowania - Google Patents

Peptydy immunosupresyjne i ich zastosowania

Info

Publication number
PL419327A1
PL419327A1 PL419327A PL41932716A PL419327A1 PL 419327 A1 PL419327 A1 PL 419327A1 PL 419327 A PL419327 A PL 419327A PL 41932716 A PL41932716 A PL 41932716A PL 419327 A1 PL419327 A1 PL 419327A1
Authority
PL
Poland
Prior art keywords
applications
immunosuppressive peptides
amino acid
application
acid sequence
Prior art date
Application number
PL419327A
Other languages
English (en)
Other versions
PL238939B1 (pl
Inventor
Krystyna OKONIEWSKA
Anna KĘDZIERSKA
Anna CHEŁMOŃSKA-SOYTA
Anna SŁAWEK
Original Assignee
Przedsiębiorstwo Farmaceutyczne Okoniewscy Vetos-Farma Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Przedsiębiorstwo Farmaceutyczne Okoniewscy Vetos-Farma Spółka Z Ograniczoną Odpowiedzialnością filed Critical Przedsiębiorstwo Farmaceutyczne Okoniewscy Vetos-Farma Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL419327A priority Critical patent/PL238939B1/pl
Priority to PCT/PL2017/050054 priority patent/WO2018084731A1/en
Publication of PL419327A1 publication Critical patent/PL419327A1/pl
Publication of PL238939B1 publication Critical patent/PL238939B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem zgłoszenia jest peptyd posiadający sekwencję aminokwasową wybraną spośród sekwencji nr 1 - 20, przeznaczony do stosowania w farmacji oraz do stosowania w immunosupresji, zwłaszcza do indukowania funkcji lub liczby limfocytów T regulatorowych. Zgłoszenie obejmuje też sposób zwiększania immunogenności białek, znamienny tym, że ze struktury białka usuwa się sekwencję aminokwasową wybraną spośród sekwencji nr 1 - 20.
PL419327A 2016-11-02 2016-11-02 Peptyd immunosupresyjny i jego zastosowania PL238939B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL419327A PL238939B1 (pl) 2016-11-02 2016-11-02 Peptyd immunosupresyjny i jego zastosowania
PCT/PL2017/050054 WO2018084731A1 (en) 2016-11-02 2017-11-02 Immunosuppressive peptides and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL419327A PL238939B1 (pl) 2016-11-02 2016-11-02 Peptyd immunosupresyjny i jego zastosowania

Publications (2)

Publication Number Publication Date
PL419327A1 true PL419327A1 (pl) 2018-05-07
PL238939B1 PL238939B1 (pl) 2021-10-18

Family

ID=62062393

Family Applications (1)

Application Number Title Priority Date Filing Date
PL419327A PL238939B1 (pl) 2016-11-02 2016-11-02 Peptyd immunosupresyjny i jego zastosowania

Country Status (2)

Country Link
PL (1) PL238939B1 (pl)
WO (1) WO2018084731A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114512179B (zh) * 2022-02-02 2024-09-24 上海图灵智算量子科技有限公司 基于量子互学习机制的结合能预测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2450368A1 (en) * 2007-01-30 2012-05-09 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
ES2702676T3 (es) * 2014-04-01 2019-03-04 Inst Nat Sante Rech Med Péptido de donante aislado derivado de MHC y usos del mismo
EP3185885B1 (en) * 2014-08-26 2020-08-19 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of autoimmune disorders

Also Published As

Publication number Publication date
PL238939B1 (pl) 2021-10-18
WO2018084731A1 (en) 2018-05-11

Similar Documents

Publication Publication Date Title
MX2016008958A (es) Proteinas quimericas de factor viii y usos de estas.
CO2018011668A2 (es) Neoantígenos y métodos de su uso
EA201992063A1 (ru) СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
BR112019018307A2 (pt) Plataforma para identificação de peptídeos imunogênicos baseada em população
BR112019011277A2 (pt) polinucleotídeo, sistema de expressão recombinante, vetor, polipeptídeo, célula recombinante, polipeptídeo de receptor imune sintético isolado ou heterodímero de polipeptídeo, célula efetora imune ou célula-tronco, população de células imunes ou efetoras, métodos de fabricação de uma célula efetora imune que expressa sir, de geração de uma população de células modificadas por rna, de fornecimento de imunidade antidoença e de tratamento ou prevenção de uma doença, composição, uso ou método, kit, e, sequência de aminoácidos.
WO2018187356A3 (en) Protein antigens and uses thereof
UY40283A (es) Método para alterar una propiedad de una planta
HRP20210734T1 (hr) Koštani morfogenetski proteini
BR112019008351A2 (pt) imunoglobulinas e usos das mesmas
DK3707261T3 (da) Fusionsproteiner baseret på humant ferritin og protease-spaltbare peptider og deres anvendelse som kemoterapi-bærestoffer
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
MX2018000697A (es) Peptidos anti-inflamatorios y usos de los mismos.
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
BR112018013246A2 (pt) rótulo de peptídeo e proteína rotulada incluindo o mesmo
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
EA201791918A1 (ru) Модификация белков клеток-хозяев
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
PL415888A1 (pl) Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie
EA202090143A1 (ru) Фармацевтически приемлемые соли полипептидов и их применение
EP3840766A4 (en) Collections of peptides, peptide agents, and methods of use thereof
GB2561755A8 (en) Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
PE20180162A1 (es) Polipeptidos dirigidos a la fusion de vih
PL419327A1 (pl) Peptydy immunosupresyjne i ich zastosowania
HK1249092A1 (zh) 用於样品制备尤其是用於质谱分析的方式和方法